S-1/A: Papa Medical Inc. Files S-1/A for IPO Amidst Regulatory Headwinds

Papa Medical Inc. is pursuing an initial public offering of 3.75 million Class A common shares at $4.00 per share, aiming to raise $12.8 million, while facing significant regulatory changes impacting a substantial portion of its Hemp cannabinoid E-vapors business.

Summary

• Papa Medical Inc. is offering 3,750,000 shares of Class A common stock at an estimated initial public offering price of US$4.00 per share, seeking to raise approximately US$12,817,000 in net proceeds.
• The company intends to list its Class A common stock on the Nasdaq Capital Market under the symbol PAPA, with the offering contingent upon final Nasdaq listing approval.
• A significant regulatory change, the 2026 Federal Appropriations Bill, effective November 12, 2026, will reclassify Delta-8 THC products as Schedule 1 marijuana, prohibiting their sale.
• Revenues from these 'Future Excluded Products' accounted for 35.0% of Hemp sales and 29.2% of total revenues in 2025, indicating a material adverse effect on future business.
• The company plans to mitigate this impact through global expansion into new medical markets and diversification into medical products, including home-use nebulizers and pulmonary function testing devices.
• For the year ended December 31, 2025, total revenues increased by 33.3% to US$50.3 million from US$37.7 million in 2024, driven by Hemp cannabinoid E-vapors and medical nebulizer sales.
• Net income increased by 21.6% to US$1.0 million in 2025 from US$0.9 million in 2024.
• Cash flow from operating activities shifted from a positive US$1.8 million in 2024 to a negative US$2.8 million in 2025.
• The company operates as an end-to-end innovative Hemp dosing solutions provider, leveraging AiMesh and feelmixX technologies, and is also involved in the nebulizer industry.
• Mr. Jian Hua, CEO and director, holds 96.57% of the company's voting power, making it a controlled company under Nasdaq rules, which allows for certain corporate governance exemptions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution. While revenue and net income show growth, the impending regulatory ban on a significant portion of the company's core business (Delta-8 THC) and the negative shift in operating cash flow present substantial future challenges that outweigh the positives of the IPO and diversification strategy.

Positives

• Total revenues increased by 33.3% from US$37.7 million in 2024 to US$50.3 million in 2025, primarily due to expanded Hemp cannabinoid E-vapors customer base and sales of newly developed medical nebulizers.
• Gross profit increased by 26.0% from US$9.4 million in 2024 to US$11.9 million in 2025, driven by increased sales volume and customer demand.
• Net income increased by 21.6% from US$0.9 million in 2024 to US$1.0 million in 2025.
• The company possesses innovative atomization (AiMesh) and aroma molecule blending (feelmixX) technologies, facilitating precise dosing control and enhanced user experience.
• Strategic plans include global expansion into new regional medical markets, R&D innovation for new medical products (e.g., home-use nebulizers, pulmonary function testing devices), and diversification into Class II medical devices and consumables.
• The company aims to scale up production through its wholly-owned subsidiary, AirICU INC., enriching its product portfolio and increasing market opportunities.
• Positioned as a leading provider of 'No Heat No Burn' (NHNB) healthier nicotine ingestion experience, according to the Frost & Sullivan Report.
• The U.S. Hemp cannabinoid E-liquid industry market size is projected to grow from USD4,040.0 million in 2026 to USD8,056.0 million in 2030, with a CAGR of 18.8%.
• The U.S. nebulizer market is expected to grow from USD1.9 billion in 2021 to USD2.9 billion in 2025 (CAGR 11.7%), and further to USD2,641.3 million in 2030 (CAGR 10.7%), driven by technology advancements and home healthcare demand.

Negatives

• The 2026 Federal Appropriations Bill, effective November 12, 2026, will prohibit the sale of Delta-8 THC products, which accounted for 29.2% of total revenues in 2025, posing a material adverse effect on future revenues and business.
• Cash and cash equivalents significantly decreased from US$4.7 million in 2024 to US$1.2 million in 2025.
• Net cash flow from operating activities shifted from a positive US$1.8 million in 2024 to a negative US$2.8 million in 2025.
• Gross profit margin decreased from 24.9% in 2024 to 23.6% in 2025, attributed to volume-related cost increases not fully offset by economies of scale and product mix adjustments.
• The company has significant concentration risks, with two customers collectively representing approximately 63.2% of total revenues in 2025, and three suppliers accounting for 40.8%, 20.3%, and 19.9% of total accounts payable in 2025.
• Extensive related party transactions exist, with Mr. Jian Hua (CEO and principal shareholder) controlling Shenzhen Feellife, from which the company made US$2.7 million in purchases in 2025 and to which it transferred US$3.18 million in net amounts due from other related parties.
• The company is a 'controlled company' due to Mr. Jian Hua's 96.57% voting power, allowing it to rely on certain Nasdaq corporate governance exemptions, which may reduce protections for other shareholders.
• The initial public offering price is substantially higher than the net tangible book value per share, resulting in immediate and substantial dilution of US$3.42 per share for new investors.
• Substantially all executive officers and directors are located in mainland China, making it difficult for U.S. stockholders to effect service of process or enforce U.S. judgments.

Risks

• Enaction of certain provisions under the 2026 Federal Appropriations Bill, effective November 12, 2026, will materially and adversely affect business operations by reclassifying Delta-8 THC products as Schedule 1 marijuana, prohibiting their sale.
• State-level regulation of hemp products is rapidly developing and changes to enforcement priorities at the state-level could negatively impact business, including potential repeal of laws permitting business or products.
• Existing laws, regulations, and policies, and the issuance of new or more stringent ones in relation to the E-vapors and/or Hemp cannabinoid vapor industry, can materially and adversely affect business operations.
• The FDA could change its enforcement priorities with respect to cannabis and hemp-derived products, potentially leading to stricter licensing, compliance obligations, or outright prohibitions.
• Products could be subject to product liability legal claims as a result of adverse events, leading to significant insurance and loss expenses, and negative publicity.
• Legal proceedings alleging violations of the Federal Paraphernalia Law or changes in its interpretation could adversely affect business, financial condition, or results of operations.
• Mr. Jian Hua, as the chief executive officer and director, holds 96.57% of common stock and 70.0% of a related party (Shenzhen Feellife), creating potential conflicts of interest.
• Reliance on related parties for business process outsourcing and leased properties exposes the company to risks of operational interruptions or unfavorable terms if relationships deteriorate.
• Legislation and regulations relating to delivery, sales, and shipping restrictions of tobacco products (including E-vapors) in the United States, such as the PACT Act, may make it more difficult and costly to sell products.
• If the use of Hemp cannabinoid E-vapors and consuming E-vapors is determined or perceived to pose long-term health risks, product use may decline significantly.
• The E-vapors market may develop more slowly or differently than expected due to uncertainties in acceptance, health studies, economic conditions, and regulatory landscape.
• Intense competition from companies in the E-vapors industry and other sources of nicotine and Hemp could adversely affect results of operations, market share, and brand recognition.
• Infringement of intellectual property by third parties or loss of intellectual property rights may materially and adversely affect business, financial condition, and results of operations.
• Competition for highly skilled employees is intense, and inability to attract and retain them could adversely affect efficiency and operations.
• Internal control over financial reporting may not be effective, and deficiencies could have a material adverse effect on business and reputation.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to the small public offering size and large insider holdings, potentially delaying or denying listing.
• Cyber-attacks and security vulnerabilities could result in serious harm to reputation, business, and financial condition, as evidenced by a recent ransomware incident at a representative.

Future Outlook

The company plans to mitigate the material adverse effect of the 2026 Federal Appropriations Bill (prohibiting Delta-8 THC sales from November 12, 2026) by continuing to sell compliant Hemp products, expanding globally into new regional medical markets, and diversifying into the medical products sector, including Class II medical devices and consumables. It intends to enhance and expand medical product lines through its subsidiary, AirICU INC., and remains committed to R&D innovation for new products like home-use nebulizers and pulmonary function testing devices. The company expects to recognize the US$2.8 million balance of contract liabilities as revenue within the next 12 months.

Management Comments

• Management believes its full-cycle operations and leading market position will enable it to further capitalize on the growth potential of the Hemp cannabinoid E-vapors market in the United States.
• Management believes the application of its feelmixX technology effectively improves users' vaping experience and creates new possibilities for the innovation and development of Hemp dosing products.
• Management believes the company's industry-leading quality assurance and control practices and technology and product development capabilities are essential to its success.
• Management believes that the company has the ability to evaluate and quickly respond to market needs for E-vapors and develop products for both Hemp cannabinoid E-vapors and consuming E-vapors markets.
• Management believes that current cash, cash generated from operations, and access to capital markets will be sufficient to meet working capital needs for at least the next twelve months, and is not dependent on future financing from related parties.

Industry Context

StockSavvy.ai notes that Papa Medical Inc. operates in the rapidly evolving and highly competitive Hemp dosing and nebulizer industries. While the Hemp cannabinoid E-liquid market in the US is projected for robust growth (18.8% CAGR from 2026-2030), the company faces significant regulatory headwinds with the impending ban on Delta-8 THC products, which represent a substantial portion of its current revenue. The diversification into medical nebulizers, a market also experiencing strong growth (11.2% CAGR from 2026-2030), is a strategic move to offset these risks. The company's 'end-to-end' solution provider model and proprietary technologies like AiMesh and feelmixX are presented as competitive advantages in a fragmented market with over 400 participants, where it claims a 'first-mover advantage' in medical atomization background and NHNB technology.

Comparison to Industry Standards

• The U.S. Hemp cannabinoid E-liquid industry market size increased from USD1,701.5 million in 2021 to USD3,298.3 million in 2025, with a CAGR of 18.0%. Papa Medical's revenue growth of 33.3% from 2024 to 2025 outpaced this industry average, indicating strong market penetration in its existing product lines.
• The U.S. Hemp cannabinoid E-vapor market grew from USD945.3 million in 2021 to USD1,534.1 million in 2025, representing a CAGR of 12.9%. Papa Medical's focus on this segment aligns with a growing market.
• The U.S. nebulizer market expanded from USD1.9 billion in 2021 to USD2.9 billion in 2025, achieving a CAGR of 11.7%. Papa Medical's entry and growth in this sector, with medical nebulizer revenue increasing from US$2.6 million in 2024 to US$3.3 million in 2025, positions it in a growing segment driven by respiratory ailments and home healthcare demand.
• The company is identified by the Frost & Sullivan Report as the 'first end-to-end innovative Hemp dosing solution provider in the US that possesses the medical atomization or nebulizing background and sells nebulizers,' suggesting a unique market position compared to traditional vaping corporations or Hemp dosing product brand operators.
• Papa Medical is also noted as 'one of the few end-to-end innovative Hemp dosing solution providers in the US that engage in the revolutionization of healthier nicotine ingestion experience with NHNB,' indicating a competitive edge in advanced vaping technology.

Management Changes

Corporate Governance

Legal Proceedings

• Joel Adalberto Gallo, an independent director candidate, was a co-defendant in a securities class action lawsuit (Daniel Perrier v. Hywin Holdings Ltd., et al.) filed in March 2024 in New York, alleging misstatements/omissions in offering documents related to Hywin Holdings Ltd.'s exposure to distressed real estate developers. The lawsuit has been finalized and approved for settlement, and it is not expected to materially impact Mr. Gallo's ability to serve or the company's business.
• The company is subject to legal proceedings and regulatory actions in the ordinary course of business, but as of the prospectus date, is not a party to any material legal or administrative proceedings expected to have a material adverse effect on its consolidated business, financial position, cash flows, or results of operations.

Related Party Transactions

• Mr. Jian Hua, the CEO and director, holds 96.57% of the company's common stock and 70.0% of Shenzhen Feellife, a related party.
• The company purchased approximately US$2.7 million from Shenzhen Feellife in 2025 (US$4.2 million in 2024) for consumable E-vapors, packaging materials, and mold equipment.
• The company made sales to Shenzhen Feellife amounting to approximately US$1.6 million in 2025 (US$0.01 million in 2024).
• Based on a Debit Waiver Agreement dated April 1, 2024, the company transferred net amounts due from thirteen other related parties to Shenzhen Feellife, totaling US$3,179,794 for 2025 and US$374,951 for 2024. These transfers are irrevocable, unsecured, without fixed terms, and interest-free.
• The company entered into a business process outsourcing service agreement with Shenzhen Feellife (effective January 1, 2022, to December 31, 2026) for R&D, marketing, financial expertise, production management, and business process design and operation, with service expenses of US$2,229,432 in 2025 (US$2,240,245 in 2024).
• The company leases 18,000 square feet of real estate in California from Cpresso, LLC, a related party controlled by close family members of the CEO, under a lease agreement effective January 1, 2021, to December 31, 2026. Rental expenses were US$453,000 in 2025 (US$96,000 in 2024). Lease rates with Cpresso, LLC were more favorable than market rates but are expected to be adjusted to market rates from January 1, 2025.
• The CEO, Mr. Jian Hua, had US$1,341 due to him as of December 31, 2025, for office expense reimbursements.

Stakeholder Impact

• **Shareholders**: New investors will experience immediate and substantial dilution of US$3.42 per share. Existing shareholders, particularly Mr. Jian Hua, will retain significant voting control (91.63% post-IPO), limiting the influence of other shareholders on corporate matters. The impending ban on Delta-8 THC products could materially reduce future revenues and profitability, impacting shareholder value.
• **Employees**: The company's growth strategies, including R&D innovation and scaling up production, could create new opportunities. However, the intense competition for highly skilled employees and the potential impact of regulatory changes on business operations pose risks to job security and growth.
• **Customers**: Customers of Delta-8 THC products will be affected by the November 12, 2026, prohibition. The company's diversification into medical products and global expansion aims to offer new product lines and solutions, potentially benefiting new customer segments while retaining existing compliant Hemp product customers.
• **Suppliers**: The company has significant concentration risks with major suppliers, meaning any interruption or change in policy from these suppliers could materially impair the company's ability to operate and generate revenue.
• **Creditors**: The shift to negative cash flow from operations and the significant decrease in cash and cash equivalents could raise concerns for creditors, although the IPO is expected to provide a capital injection. The company's ability to manage working capital and secure future financing will be crucial.

Next Steps

• Continue offering and selling 'Future Excluded Products' (Delta-8 THC) until November 12, 2026.
• Destroy any remaining 'Future Excluded Products' prior to November 12, 2026.
• Implement strategies of global expansion into new regional medical markets.
• Implement diversification by exploring the medical products sector, including Class II medical devices and medical consumables.
• Enhance and expand medical product lines through the wholly-owned subsidiary, AirICU INC.
• Continue R&D innovation to support development of new products, such as home-use nebulizers and pulmonary function testing devices.
• Complete the initial public offering and list Class A common stock on the Nasdaq Capital Market under the symbol PAPA.
• Establish an audit committee, compensation committee, and nominations committee under the board of directors prior to IPO completion.
• File the Final Prospectus with the SEC in accordance with Rules 424(b) and 430A under the Securities Act.
• Make generally available an earning statement satisfying Section 11(a) of the Securities Act covering at least 12 months beginning with the first fiscal quarter after the Registration Statement's effective date.

Key Dates

Recommendation

The impending regulatory ban on Delta-8 THC products, which constituted nearly 30% of Papa Medical Inc.'s total revenue in 2025, represents a severe and unavoidable headwind. While the company outlines diversification strategies, the magnitude of this revenue loss, coupled with a significant negative shift in operating cash flow and a substantial decrease in cash reserves, creates considerable uncertainty and risk for future profitability and liquidity. The immediate and substantial dilution for new investors in the IPO further diminishes the attractiveness of the offering. Despite some revenue growth, the fundamental business model faces a major disruption, making the stock a high-risk investment with a strong likelihood of underperformance.

Keywords

Hemp cannabinoid E-vapors, Nebulizers, IPO, SEC S-1/A, Delta-8 THC, Medical devices, Vaping technology, AiMesh technology, feelmixX technology, No Heat No Burn (NHNB), Nasdaq Capital Market, Regulatory risk, Controlled company, Related party transactions, Financial performance, Capital raise, Product development, Global expansion